Program
azenosertib
Also written as “Azenosertib” and “ZN-c3”.
Its studies are mostly in Ovarian Neoplasms · Osteosarcoma · Cystadenocarcinoma, Serous · Colorectal Neoplasms · Leukemia, Myeloid, Acute, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | 72 open or running | phase 3since Mar 26, 2026 | Nov 4, 2019 | Dec 1, 2026phase 2 · NCT05128825 |
| K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | 10 open or running | phase 2since Dec 19, 2022 | Dec 19, 2022 | none ahead |
| Zentera Therapeutics HK | 10 open or running | phase 1since Jul 12, 2021 | Jul 12, 2021 | none ahead |
Also a collaborator on its studies: Pfizer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 4, 2019First study: phase 1 study in Solid TumorNew to K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT04158336 · 274 enrolled · United States
- Mar 18, 2021Phase 2 study in Cystadenocarcinoma, SerousK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT04814108 · 92 enrolled · United States, Australia, Canada and more
- Mar 25, 2021Phase 1 study in OsteosarcomaK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT04833582 · 31 enrolled · United States, France
- Jul 12, 2021Zentera Therapeutics HK's first study: phase 1 study in Solid TumorsNew to Zentera Therapeutics HKZentera Therapeutics HK · NCT04972422 · 38 enrolled · China
- Oct 28, 2021Phase 2 study in Ovarian NeoplasmsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT05128825 · 310 planned · United States, Australia, Belgium and more
- Dec 8, 2021Phase 2 study in Ovarian NeoplasmsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT05198804 · 117 enrolled · United States, France
- Dec 19, 2022K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals's first study: phase 2 study in Leukemia, Myeloid, AcuteNew to K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT05682170 · 40 enrolled · United States
- Jan 26, 2023Phase 1 study in Colorectal NeoplasmsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT05743036 · 44 enrolled · United States, Australia, Germany and more
- Mar 26, 2026Phase 3 study in Ovarian NeoplasmsPhase 3 reachedK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT07546500 · 420 planned · United States, Argentina, Australia and more
Ahead
- Dec 1, 2026Primary completion: phase 2 study in Ovarian NeoplasmsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT05128825
- May 31, 2028Primary completion: phase 3 study in Ovarian NeoplasmsK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals · NCT07546500
TargetBeta
“Serine/threonine-protein kinase WEE1 inhibitor”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07546500Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | May 31, 2028 | 420 |
| NCT05743036Colorectal Neoplasms · United States, Australia, Germany and more | 1 | Terminated | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | Jul 16, 2024 | 44 |
| NCT05682170Leukemia, Myeloid, Acute · United States | 2 | Terminated | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | Jul 2, 2024 | 40 |
| NCT05198804Ovarian Neoplasms · United States, France | 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | Oct 15, 2025 | 117 |
| NCT05128825Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | Dec 1, 2026 | 310 |
| NCT04972422Solid Tumors · China | 1 | UNKNOWN | Zentera Therapeutics HK | Jun 30, 2022 | 38 |
| NCT04833582Osteosarcoma · United States, France | 1 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | Aug 30, 2023 | 31 |
| NCT04814108Cystadenocarcinoma, Serous · United States, Australia, Canada and more | 2 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | Oct 22, 2025 | 92 |
| NCT04158336Solid Tumor · United States | 1 | Completed | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals | May 6, 2025 | 274 |
How it is read
Names in the registry
- “Azenosertib”, 5 entries
- “ZN-c3”, 3 entries
- “azenosertib”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 3 studies
- Osteosarcoma, 1 study
- Cystadenocarcinoma, Serous, 1 study
- Colorectal Neoplasms, 1 study
- Leukemia, Myeloid, Acute, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.